HTG Molecular Diagnostics Announces the Next Event in its RNA Profiling in Drug Discovery KOL Webcast Series
TUCSON, Ariz., Dec. 09, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...
Pharmaceutical
Optinose Announces Departure of Acting Chief Financial Officer
YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose...
BBS-Bioactive Bone Substitutes: 69% of the warrants 1-2022 (WA1) used for the subscription of shares, company raises EUR 213 000 in gross proceeds
BBS-Bioactive Bone Substitutes Oyj, Company Announcement, 9 December 2022 at 2.15 p.m. EET BBS-Bioactive Bone Substitutes: 69% of the warrants...
ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9, 2022 –...
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza
NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced...
Sirona Biochem Announces Start of Clinical Trial for Anti-Aging Compound TFC-1326
VANCOUVER, British Columbia, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is...
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a...
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company...
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
MENLO PARK, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
Company also announces that Julia Haller, MD, is stepping down from its Board of DirectorsNEW YORK, Dec. 08, 2022 (GLOBE...
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for...
Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement
ATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is...
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
Coronavirus protease inhibitor, ALG-097558, has demonstrated antiviral activity in vivo and promising pan-coronavirus activity in vitroFirst-in-human studies anticipated to begin...
Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH
Conference Call to be Held on December 14th at 11:00 a.m. Eastern TimeHOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius...
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development...
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Media Release First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi Biologics SYDNEY, AUSTRALIA, Dec. 08,...
Digipath, Inc. Announces Revenue Increase of Almost 18% for the Fourth Quarter of Fiscal Year 2022
LAS VEGAS, NV, Dec. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Digipath, Inc. (OTCQB: DIGP) (“DIGP” or the “Company”),...
HCW Biologics Enters CRADA with National Cancer Institute
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic CancerMIRAMAR, Fla., Dec. 08, 2022...
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial...